Adenovirus armed with bispecific T cell activator
US11840702B2 · kind B2 · utility
0Cited by
17References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 28, 2018 |
| Grant date | Dec 12, 2023 |
| Priority date | — |
| Expiry date | Jun 4, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An adenovirus comprising a sequence of formula (I) 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein BY comprises a transgene cassette containing four transgenes, said genes encoding a FAP-Bispecific T cell activator, CXL10, CXL9, and IFN. The disclosure also extends to a pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.